ArticleLeukemia & lymphoma2013
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
Article in Leukemia & lymphoma, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Genomics Define Malignant Transformation in Myeloma Precursor Conditions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Primum non nocere: a critical analysis of early intervention clinical trials in smoldering multiple myeloma.Frontiers in oncology · 2026Review
- Multi-omics profiling and AI-driven clinically deployable risk models in MGUS and smoldering myeloma.Clinical and experimental medicine · 2025Review
- Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis.Clinical lymphoma, myeloma & leukemia · 2025Article
- Vaccines for cancer prevention: exploring opportunities and navigating challenges.Nature reviews. Drug discovery · 2025Review
- Smoldering multiple myeloma: Integrating biology and risk into management.Seminars in hematology · 2025Review
- [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.Cancer research communications · 2023Article
- Smoldering multiple myeloma: Reviewing the rationale for intervention.Leukemia & lymphoma · 2022Article
- How I approach smoldering multiple myeloma.Blood · 2022Review
- Review
- Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.Annals of hematology · 2021Article
- Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.Nature communications · 2021Article
- Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.American journal of hematology · 2021Article
- Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma.Skeletal radiology · 2021Article
- Review
- Review
- Recent Advances in the Management of Smoldering Multiple Myeloma.World journal of oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The risk of progression to multiple myeloma (MM) from the precursor condition smoldering MM (SMM) varies considerably among individual patients. Reliable markers for progression to MM are vital to advance the understanding of myeloma precursor disease and for the development of intervention trials designed to delay/prevent MM. The Mayo Clinic and Spanish PETHEMA have proposed models to stratify patient risk based on clinical parameters. The aim of our study was to define the degree of concordance between these two models by comparing the distribution of patients with SMM classified as low, medium and high risk for progression. A total of 77 patients with SMM were enrolled in our prospective natural history study. Per study protocol, each patient was assigned risk scores based on both the Mayo and the Spanish models. The Mayo Clinic model identified 38, 35 and four patients as low, medium and high risk, respectively. The Spanish PETHEMA model classified 17, 22 and 38 patients as low, medium and high risk, respectively. There was significant discordance in overall patient risk classification (28.6% concordance) and in classifying patients as low versus high (p < 0.0001), low versus non-low (p = 0.0007) and high versus non-high (p < 0.0001) risk. There is a need for prospectively validated models to characterize individual patient risk of transformation to MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.